Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

NCT03504852 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Plaque-type Psoriasis

Interventions

DRUG: secukinumab 150 mg

Sponsor

Novartis Pharmaceuticals